4,799 Shares in Repligen Corporation $RGEN Bought by Global Retirement Partners LLC

Global Retirement Partners LLC acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN) during the second quarter, HoldingsChannel.com reports. The institutional investor acquired 4,799 shares of the biotechnology company’s stock, valued at approximately $655,000.

Several other hedge funds have also modified their holdings of RGEN. M&T Bank Corp purchased a new stake in shares of Repligen during the 4th quarter valued at $29,819,000. Avidity Partners Management LP boosted its position in shares of Repligen by 54.7% in the 1st quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after purchasing an additional 27,500 shares in the last quarter. Swedbank AB purchased a new position in Repligen during the 4th quarter worth $4,146,000. Conestoga Capital Advisors LLC grew its stake in Repligen by 10.6% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock worth $173,360,000 after buying an additional 101,062 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in Repligen during the 4th quarter valued at about $20,253,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Wolfe Research started coverage on Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target for the company. Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 13th. Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Citigroup upgraded shares of Repligen to a “buy” rating in a research note on Tuesday, July 7th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $166.43.

Insider Buying and Selling at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.60% of the company’s stock.

Repligen Trading Down 1.7%

Repligen stock opened at $166.15 on Wednesday. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77. The stock’s 50 day simple moving average is $144.29 and its two-hundred day simple moving average is $131.18. The firm has a market cap of $9.38 billion, a PE ratio of 227.60, a P/E/G ratio of 3.04 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. During the same period in the previous year, the business posted $0.26 EPS. The business’s revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.